Supplementary Table S3 from Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts

Supplementary Table S3 from Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts

<p>List of differentially expressed genes associated with EMK, INT and IMP profile.</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Gabriele Todisco (15127828) (author)
Drugi avtorji:	Maria Creignou (15127831) (author), Elsa Bernard (15127822) (author), Ann-Charlotte Björklund (17141972) (author), Pedro Luis Moura (17141975) (author), Bianca Tesi (17141978) (author), Teresa Mortera-Blanco (17141981) (author), Birgitta Sander (17141984) (author), Monika Jansson (17141987) (author), Gunilla Walldin (17141990) (author), Indira Barbosa (17141993) (author), Susanne E. Reinsbach (17141996) (author), Isabel Juliana Hofman (17141999) (author), Christer Nilsson (17142002) (author), Tetsuichi Yoshizato (17142005) (author), Marios Dimitriou (17142008) (author), David Chang (17142011) (author), Svannildur Olafsdottir (17142014) (author), Sigita Venckute Larsson (17142017) (author), Magnus Tobiasson (17142020) (author), Luca Malcovati (17142023) (author), Petter Woll (17142026) (author), Sten Eirik W. Jacobsen (17142029) (author), Elli Papaemmanuil (9710965) (author), Eva Hellström-Lindberg (17142032) (author)
Izdano:	2025
Teme:	Cancer Therapeutic Research and Development Clinical Research and Trials Hematological Cancers Leukemias Precision Medicine Translational Research
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Supplementary Table S1 from Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts
od: Gabriele Todisco (15127828)
Izdano: (2025)

Supplementary Table S2 from Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts
od: Gabriele Todisco (15127828)
Izdano: (2025)

Supplementary Table S4 from Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts
od: Gabriele Todisco (15127828)
Izdano: (2025)

Supplementary Table S5 from Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts
od: Gabriele Todisco (15127828)
Izdano: (2025)

Supplemental Figure S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
od: Ibrahim Aldoss (15055961)
Izdano: (2025)

Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
od: Ibrahim Aldoss (15055961)
Izdano: (2025)

Supplemental Figure S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
od: Ibrahim Aldoss (15055961)
Izdano: (2025)

Supplemental Figure S4 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
od: Ibrahim Aldoss (15055961)
Izdano: (2025)

Supplemental Figure S5 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
od: Ibrahim Aldoss (15055961)
Izdano: (2025)

Supplementary table 5 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
od: Wei Chen (15053713)
Izdano: (2025)

Supplementary table 6 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
od: Wei Chen (15053713)
Izdano: (2025)

Supplementary table 7 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy
od: Wei Chen (15053713)
Izdano: (2025)

Supplementary Table 2 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
od: Anna Eriksson (15352461)
Izdano: (2025)

Supplementary Table1 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
od: Anna Eriksson (15352461)
Izdano: (2025)

Supplementary Tables S1-S11 from Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic <i>TP53</i>-Mutant Clonal Hematopoiesis
od: Rathana Kim (15135915)
Izdano: (2025)

Supplemental Figure 1 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
od: Amy C. Degnim (15106462)
Izdano: (2025)

Supplemental Figure 2 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
od: Amy C. Degnim (15106462)
Izdano: (2025)

Supplemental Figure 3 from Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the Breast
od: Amy C. Degnim (15106462)
Izdano: (2025)

Supplementary Data S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Supplementary Table S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Supplementary Table S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
od: Christopher T. Letson (16424095)
Izdano: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
od: Morten Lapin (15056728)
Izdano: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
od: Morten Lapin (15056728)
Izdano: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
od: Morten Lapin (15056728)
Izdano: (2025)

Supplementary Table S1 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
od: Naveen S. Vasudev (15057037)
Izdano: (2025)

Supplementary Table S2 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
od: Naveen S. Vasudev (15057037)
Izdano: (2025)

Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
od: Robert L. Hollis (15034814)
Izdano: (2025)

Figure 2 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
od: Robert L. Hollis (15034814)
Izdano: (2025)

Figure 3 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
od: Robert L. Hollis (15034814)
Izdano: (2025)

Figure 4 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
od: Robert L. Hollis (15034814)
Izdano: (2025)

Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
od: Robert L. Hollis (15034814)
Izdano: (2025)

Table 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
od: Robert L. Hollis (15034814)
Izdano: (2025)

Supplementary Figure S1 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
od: Shih-Shih Chen (15314296)
Izdano: (2025)

Supplementary Figure S2 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
od: Shih-Shih Chen (15314296)
Izdano: (2025)

Supplementary Figure S3 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
od: Shih-Shih Chen (15314296)
Izdano: (2025)

Supplementary Figure S4 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
od: Shih-Shih Chen (15314296)
Izdano: (2025)

Supplementary Figure S5 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
od: Shih-Shih Chen (15314296)
Izdano: (2025)

Supplementary Figure S6 from Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
od: Shih-Shih Chen (15314296)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_nbm3q86bmucffg1722pip99pca